PSY35 A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS EVALUATING RECENTLY APPROVED BIOLOGICAL THERAPIES FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN THE US, CANADA AND UK.

MLA

Abreu, C., et al. “Psy35 a Comparative Analysis of Health Technology Assessments Evaluating Recently Approved Biological Therapies for Adult Patients with Moderate-To-Severe Psoriasis in the Us, Canada and Uk.” Value in Health, vol. 22, Nov. 2019, pp. S907–08. EBSCOhost, https://doi.org/10.1016/j.jval.2019.09.2663.

APA

Abreu, C., Mohanty, M., & Li, J. (2019). Psy35 a Comparative Analysis of Health Technology Assessments Evaluating Recently Approved Biological Therapies for Adult Patients with Moderate-To-Severe Psoriasis in the Us, Canada and Uk. Value in Health, 22, S907–S908. https://doi.org/10.1016/j.jval.2019.09.2663

Chicago

Abreu, C., M. Mohanty, and J. Li. 2019. “Psy35 a Comparative Analysis of Health Technology Assessments Evaluating Recently Approved Biological Therapies for Adult Patients with Moderate-To-Severe Psoriasis in the Us, Canada and Uk.” Value in Health 22 (November): S907–8. doi:10.1016/j.jval.2019.09.2663.